Dawn of antimicrobials: Using phages to synergize with antibiotics to counteract bacteria
DOI:
https://doi.org/10.61173/vt0y5369Keywords:
phage therapy, phage-antibiotic combination therapy, antibiotic resistance, lysis spectrumAbstract
Currently, the misuse of antibiotics has led to a global crisis of antibiotic resistance, and people have to start seeking new strategies to solve this problem. Traditional phage therapy has been valued for its advantages of strong bactericidal efficacy and self-replication. However, the use of phage alone may confront a series of problems, such as a narrow antimicrobial spectrum, phage resistance, and immunogenicity. If phage and antibiotics are used in combination, they can synergistically lyse host bacteria and better control or eradicate bacterial infections. Therefore, their combination has recently begun to become a hotspot for research and application of phage therapy. In this paper, by collating the research literature and clinical reports on the combined application of phage and antibiotics, we explore and summarize the synergistic mechanism of phage and antibiotics, the mechanism of bacterial resistance, and the limitations of this cocktail therapy.
References
[1] Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: From biological mechanisms to future directions. Cell. 2023 Jan 5;186(1):17-31. doi: 10.1016/j.cell.2022.11.017. PMID: 36608652; PMCID: PMC9827498.
[2] Shao Jian-jian, Du Hong-xu, Qu Yi-wen, Bi Shi-cheng, Zhang Ying-ying, and Ma Yue. Combined application and its synergistic mechanisms of bacteriophages and antibiotics[J]. Chinese Journal of Antibiotics, 2022, 47(10): 985-993
[3] Cong Y, Yang S, Rao X. Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features. J Adv Res. 2019 Oct 12;21:169-176. doi: 10.1016/j.jare.2019.10.005. PMID: 32071785; PMCID: PMC7015472.
[4] Hendrix RW, Smith MC, Burns RN, et al. Evolutionary relationships among diverse bacteriophages and prophages: all the world’s a phage[J]. Proc Natl Acad Sci U S A, 1999, 96(5): 2192- 2197. DOI: 10.1073/pnas.96.5.2192.
[5] Baran A, Kwiatkowska A, Potocki L. Antibiotics and Bacterial Resistance-A Short Story of an Endless Arms Race. Int J Mol Sci. 2023 Mar 17;24(6):5777. doi: 10.3390/ijms24065777. PMID: 36982857; PMCID: PMC10056106.
[6] Gaurav A, Bakht P, Saini M, Pandey S, Pathania R. Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors. Microbiology (Reading). 2023 May;169(5):001333. doi: 10.1099/ mic.0.001333. PMID: 37224055; PMCID: PMC10268834.
[7] Gurney J, Brown SP, Kaltz O, Hochberg ME. Steering Phages to Combat Bacterial Pathogens. Trends Microbiol. 2020 Feb;28(2):85-94. doi: 10.1016/j.tim.2019.10.007. Epub 2019 Nov 16. PMID: 31744662; PMCID: PMC6980653.
[8] Comeau A M, Tetart F, Trojet S N, et al. Phage-antibiotic synergy (PAS): Beta-lactam and quinolone antibiotics stimulate virulent phage growth[J]. PLoS One, 2007, 2(8): e799.
[9] Kamal F, Dennis J J. Burkholderia cepacia complex phageantibiotic synergy (PAS): Antibiotics stimulate lytic phage activity[J]. Appl Environ Microbiol, 2015, 81(3): 1132-8.
[10] Knezevic P, Curcin S, Aleksic V, et al. Phage-antibiotic synergism: A possible approach to combatting Pseudomonas aeruginosa[J]. Res Microbiol, 2013, 164(1): 55-60.
[11] Cushnie T P T, O’driscoll N H, Lamb A J. Morphological and ultrastructural changes in bacterial cells as an indicator of antibacterial mechanism of action[J]. Cell Mol Life Sci, 2016, 73(23): 4471-4492.
[12] Kim M, Jo Y, Hwang Y J, et al. Phage-antibiotic synergy via delayed lysis[J]. Appl Environ Microb, 2018, 84(22): e02085- 18.
[13] Young R. Phage lysis: three steps, three choices, one outcome[J]. J Microbiol, 2014, 52(3): 243-258.
[14] Morrisette T, Kebriaei R, Lev K L, et al. Bacteriophage therapeutics: A primer for clinicians on phage-antibiotic combinations[J]. Pharmacotherapy, 2020, 40(2): 153-168.
[15] Gondil V S, Harjai K, Chhibber S. Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections[J]. Int J Antimicrob Agents, 2020, 55(2): 105844.
[16] Raz A, Serrano A, Hernandez A, et al. Isolation of phage lysins that effectively kill Pseudomonas aeruginosa in mouse Dean&Francis models of lung and skin infection[J]. Antimicrob Agents Ch, 2019, 63(7): e00024-19.
[17] Fischetti V A. Lysin therapy for Staphylococcus aureus and other bacterial pathogens[J]. Curr Top Microbiol Immunol, 2017, 409: 529-540
[18] Djurkovic S, Loeffler J M, Fischetti V A. Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance[J]. Antimicrob Agents Chemother, 2005, 49(3): 1225-1228.
[19] Shi X. Clinical application and mechanism of phage therapy for drug-resistant Klebsiella pneumoniae infection[D]. Shanghai: Master’s Thesis of Shanghai Jiao Tong University, 2019 (in Chinese)
[20] Nir-Paz R, Gelman D, Khouri A, Sisson BM, Fackler J, Alkalay-Oren S, Khalifa L, Rimon A, Yerushalmy O, Bader R, et al. Successful treatment of antibiotic-resistant, polymicrobial bone infection with bacteriophages and antibiotics combination[J]
[21] Schooley R T, Biswas B, Gill J J, et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection[J]. Antimicrob Agents Chemother, 2017, 61(10): 00954-17.
[22] Ma Chao, Wang Ning, Xu Yongping. Study on the combined application of phage and antibiotics to control multidrugresistant Acinetobacter baumannii [J]. Chinese Journal of Antibiotics, 2018, 43(10):1296-1297. [23] Soothill JS. Treatment of experimental infections of mice with bacteriophages. Journal of Medical Microbiology, 1992, 37(4): 258‒261.
[24] Soothill JS. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns, 1994, 20(3): 209‒211.
[25] Nouraldin A A M, Baddour M M, Harfoush R A H. Bacteriophage-antibiotic synergism to control planktonic and biofilm producing clinical isolates of Pseudomonas aeruginosa[J]. Alexandria Med J, 2016, 52(2): 99-105.
[26] Torres-Barceló C, Franzon B, Vasse M, et al. Long-term e‡ects of single and combined introductions of antibiotics an d bacteriophages on populations of Pseudomonas aeruginosa [J]. Evol Appl, 2016, 9(4): 583-595. DOI: 10.1111/eva.12364
[27] Oechslin F, Piccardi P, Mancini S, et al. Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudo monas Aeruginosa Infection in Endocarditis and Reduces Virulence [J]. J Infect Dis, 2017, 215(5): 703-712. DOI: 10.1093/i nfdis/jiw632
[28] LI Min, ZHAO Zunfu, YANG Tingting, ZHANG Huanrong. Prevention and Treatment Effect of Escherichia coli Phage BP16 on Chicken Colibacillosis[J]. China Animal Husbandry and Veterinary Medicine, 2022, 49(2): 776-782.
[29] Hong-Yu Ren, Zhen Li, Xiao-Yu Li, et al. Research progress of phage control of major enterobacterial infections [J]. Foreign medicine (antibiotic fascicle), 2019, 40(05):430-435.
[30] Tang Tao, Chen Bingbing, Long Hangyu, et al. Research on the therapeutic effect and application of phage on bacterial infection [J]. Chinese Journal of Veterinary Medicine, 2018, 54(03):50-53
[31] Tao Chenglin, Wang Shaohui, Zhang Yaodong, Yi Zhengfei, et al. Research progress and development direction of phage therapy for the prevention of bacterial infections[J]. Chinese Veterinary Science,2020,50(09):1167-1175.DOI:10.16656/ j.issn.1673-4696.2020.0164.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
